🧫 Anti-Tumor Peptide Market Analysis
Report ID: MKI-ATP-2026-001 | Release Date: July 2026
Coverage: Tumor-related peptide drugs, peptide vaccines, peptide-drug conjugates (PDCs)
1. Market Overview
Anti-tumor peptides represent the second largest therapeutic application area in the peptide drug field after GLP-1. In 2024, the global anti-tumor peptide drug market size was approximately $5.8B, projected to reach $12.0B by 2030, with a CAGR of approximately 12.8%.
Market Drivers
- Growth of immune checkpoint inhibitor combination with peptide vaccine regimens
- Peptide-drug conjugates (PDCs) as alternative/complementary therapies to ADCs
- Personalized tumor vaccine technology maturing
- Precision oncology driving targeted peptide development
2. Market Segmentation and Product Classification
2.1 By Therapeutic Mechanism
| Category |
2024 Market Size ($B) |
Share |
Growth CAGR |
Representative Drugs |
| LHRH Analogs (Endocrine Therapy) |
$2.8 |
48% |
+5% |
Leuprolide, Goserelin, Triptorelin |
| Peptide-Drug Conjugates (PDCs) |
$0.6 |
10% |
+25% |
Lutathera (β-radiation), PEP-010 |
| Peptide Tumor Vaccines |
$0.5 |
9% |
+18% |
Personalized neoantigen vaccines |
| Tumor-Targeting Peptides |
$0.3 |
5% |
+20% |
Integrin-targeting peptides, RGD peptides |
| Antimicrobial/Antiviral (Tumor-Related) |
$0.4 |
7% |
+8% |
Polymyxins, anti-infective adjuvant therapy |
| Other Therapeutic Peptides |
$1.2 |
21% |
+10% |
Multiple mechanisms |
2.2 LHRH Analog Segment
LHRH agonists and antagonists are the largest category within anti-tumor peptides, primarily used for prostate cancer and breast cancer:
| Drug |
Brand |
Company |
2024 Global Sales ($B) |
Primary Indications |
| Leuprolide |
Lupron/Enantone |
AbbVie/Takeda |
$1.2 |
Prostate cancer, breast cancer |
| Goserelin |
Zoladex |
AstraZeneca |
$0.9 |
Prostate cancer, breast cancer |
| Triptorelin |
Decapeptyl |
Ipsen |
$0.5 |
Prostate cancer |
| Degarelix |
Firmagon |
Ferring |
$0.2 |
Prostate cancer |
3. Peptide Tumor Vaccines
3.1 Technology Route Classification
| Technology Route |
Representative Companies |
Progress |
Characteristics |
| Neoantigen Peptide Vaccines |
BioNTech/Moderna/Gritstone |
Phase II-III |
Personalized, mRNA + peptide combination |
| Shared Antigen Peptide Vaccines |
ISA Pharmaceuticals |
Phase II |
HPV16-positive tumors |
| Peptide-Pulsed DC Vaccines |
Multiple companies |
Phase II |
Ex vivo peptide-loaded dendritic cell reinfusion |
| Peptide/Adjuvant Combination Vaccines |
Chinese Academy of Sciences / Multiple |
Phase I-II |
Combined with TLR agonists and other adjuvants |
3.2 Key Clinical Progress
| Program |
Company |
Indication |
Clinical Stage |
Recent Data |
| UV1 Peptide Vaccine |
Ultimovacs |
Melanoma/NSCLC |
Phase III |
Phase II OS benefit trend |
| PDS0101 |
PDS Biotechnology |
HPV16+ Oropharyngeal Cancer |
Phase III |
Combined with Pembrolizumab ORR 44% |
| NeoVax |
Dana-Farber Cancer Institute |
Melanoma |
Phase II |
Long-term OS benefit |
4. Peptide-Drug Conjugates (PDCs)
4.1 PDC vs ADC Comparison
| Feature |
PDC (Peptide-Drug Conjugate) |
ADC (Antibody-Drug Conjugate) |
| Targeting Carrier |
Peptide (10-30 amino acids) |
Monoclonal antibody (~150 kDa) |
| Molecular Weight |
1-5 kDa |
~150 kDa |
| Tumor Penetration |
High, easily penetrates tumor tissue |
Limited, solid tumor penetration moderate |
| Immunogenicity Risk |
Low |
Medium-High |
| Synthesis Difficulty |
Moderate (solid-phase synthesis) |
High (cell culture) |
| Production Cost |
Low |
High |
| Marketed Products |
1 (Lutathera) |
15+ |
4.2 PDC Pipeline in Development
| Drug |
Company |
Target |
Payload |
Indication |
Stage |
| Lutathera |
Novartis/AAA |
SSTR2 |
¹⁷⁷Lu-peptide |
Neuroendocrine tumors |
✅ Marketed |
| PEP-010 |
Netherlands Cancer Institute |
p53/Bcl-2 |
Cell-penetrating peptide |
Solid tumors |
Phase II |
| CBX-12 |
Cybrexa |
PSMA |
Doxorubicin |
Prostate cancer |
Phase I |
| PHI-101 |
Pi Health |
Multi-target |
Chemotherapy drug |
Leukemia |
Phase I |
| ¹⁸⁸Re-P2045 |
Multiple |
SSTR2 |
¹⁸⁸Re |
NET |
Phase I/II |
5. Tumor-Targeting Peptides
5.1 Major Targeting Mechanisms
| Targeting Mechanism |
Target |
Application Direction |
Clinical Progress |
| Integrin Targeting (RGD peptides) |
αvβ3/αvβ5 |
Tumor vascular targeting |
Entered clinical trials |
| Somatostatin Analogs |
SSTR2/5 |
NET imaging + therapy |
Marketed (Octreotide, etc.) |
| Gastrin-Releasing Peptide Receptor |
GRPR |
Prostate cancer |
Phase II |
| Neurotensin Receptor |
NTR1 |
Breast/colon cancer |
Preclinical/Phase I |
| Special Structure Peptides |
Multiple |
Cell penetration |
Preclinical |
6. R&D Pipeline Panorama
6.1 By Clinical Stage Distribution
| Stage |
Pipeline Count (Global) |
Share |
| Marketed |
~30 |
5% |
| Phase III |
20+ |
3% |
| Phase II |
80+ |
13% |
| Phase I |
200+ |
33% |
| Preclinical |
280+ |
46% |
6.2 China Anti-Tumor Peptide Pipeline
| Company |
Program |
Type |
Indication |
Stage |
| Hengrui Medicine |
SHR-1701 |
Bifunctional fusion peptide |
Solid tumors |
Phase II |
| Innovent Biologics |
IBI-188 |
Peptide analog |
Oncology |
Phase I |
| Hisun Pharma |
Peptide anticancer drug |
LHRH analog |
Prostate cancer |
Marketed |
| Huahai Pharma |
Multiple generic peptides |
LHRH class |
Breast/prostate cancer |
Marketed |
7. Market Outlook and Prospects
7.1 Key Drivers
| Driver |
Impact Level |
Description |
| Precision Oncology |
★★★★★ |
Personalized peptide tumor vaccines will become core precision medicine tools |
| PDC Replacing ADC |
★★★★☆ |
PDC tumor penetration and cost advantages hold great potential in solid tumors |
| Immunotherapy Combinations |
★★★★☆ |
Peptide vaccine + ICI combination regimens improving ORR |
| Rising Geriatric Cancer Incidence |
★★★★☆ |
Stable long-term demand for LHRH analogs |
| Chinese Innovative Drug Going Global |
★★★☆☆ |
Chinese companies accelerating PDC pipeline development |
7.2 Market Size Forecast
| Year |
Global Market ($B) |
LHRH Class ($B) |
PDC ($B) |
Peptide Vaccines ($B) |
Others ($B) |
| 2024 |
$5.8 |
$2.8 |
$0.6 |
$0.5 |
$1.9 |
| 2026E |
$7.2 |
$3.0 |
$1.0 |
$0.8 |
$2.4 |
| 2028E |
$9.5 |
$3.2 |
$1.8 |
$1.3 |
$3.2 |
| 2030E |
$12.0 |
$3.5 |
$2.8 |
$2.0 |
$3.7 |
Conclusion
Anti-tumor peptides represent a diverse and deep niche market. LHRH analogs form a stable foundation, while PDCs and peptide tumor vaccines represent the fastest-growing emerging directions. With the development of precision oncology and maturation of PDC technology, the anti-tumor peptide market will double by 2030.
Data Sources
Data compiled from Evaluate Pharma, Pharmaprojects, company annual reports, and ClinicalTrials.gov.
Anti-Tumor Peptide CDMO Services → SENO Biotechnology Professional Team. SENO Biotechnology provides custom synthesis, process development, and commercial production services for anti-tumor peptide APIs and intermediates, supporting GMP-grade production to accelerate the R&D and market launch of anti-tumor peptide drugs.